BDR Pharma introduces prostate most cancers drug with enhanced power


BDR Pharmaceuticals on Monday stated it has launched prostate most cancers remedy drug Enzalutamide in 160 mg power.


The corporate has launched the treatment, below the model title BDENZA 160mg, at Rs 6,300 for a strip of seven tablets.





The drugs was beforehand out there in 40 mg and 80 mg power for which sufferers needed to devour two tablets a day.


The target behind the launch of Enzalutamide 160 mg is to make sure higher efficacy, minimal unwanted effects, include relapse instances by blocking the hormones of most cancers cells offering an advanced remedy, BDR Pharmaceuticals stated in an announcement.


“Our targeted launch of such expanded model power will certainly add worth to Indian oncology sufferers in addition to present alternative for medical physicians to adjust to affected person final result and normal remedy protocol.


“This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high quality standards,” BDR Pharmaceuticals Director Enterprise Improvement Raheel Shah famous.

(Solely the headline and movie of this report could have been reworked by the Enterprise Normal employees; the remainder of the content material is auto-generated from a syndicated feed.)

Pricey Reader,

Enterprise Normal has all the time strived exhausting to offer up-to-date data and commentary on developments which can be of curiosity to you and have wider political and financial implications for the nation and the world. Your encouragement and fixed suggestions on tips on how to enhance our providing have solely made our resolve and dedication to those beliefs stronger. Even throughout these troublesome instances arising out of Covid-19, we proceed to stay dedicated to preserving you knowledgeable and up to date with credible information, authoritative views and incisive commentary on topical problems with relevance.

We, nevertheless, have a request.

As we battle the financial affect of the pandemic, we want your help much more, in order that we will proceed to give you extra high quality content material. Our subscription mannequin has seen an encouraging response from a lot of you, who’ve subscribed to our on-line content material. Extra subscription to our on-line content material can solely assist us obtain the objectives of providing you even higher and extra related content material. We consider in free, honest and credible journalism. Your help by way of extra subscriptions may help us practise the journalism to which we’re dedicated.

Assist high quality journalism and subscribe to Enterprise Normal.

Digital Editor

Leave a Reply

Your email address will not be published.